Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why 4basebio PLC (4BB) Deserves a Fresh Look as Its Synthetic DNA Business Scales Up

The question is whether that activity converts into orders quickly enough. 4basebio ended 2025 with £17.8 million of cash and has since drawn a further €7 million under an existingDebtfacility, which the board says funds the group into late 2027. At 475p on 2 …

Ankur Sharma | 10 September 2026

Is Craneware plc (CRW) a Sleeper Stock Investors Should Be Watching in 2026?

Full-year results are due this month, and the central question is whether the slippage in 340B and enterprise contract revenue is a timing problem, as management insists, or a sign of a tougher market.

Ankur Sharma | 10 September 2026

Abingdon Health Plc (LSE:ABDX) in Focus: Is This a Diagnostics CDMO Story the Market Is Underestimating?

That gap frames the question ahead of full results in early October: has Abingdon quietly turned the corner, with a contracted pipeline supporting what management calls "significant revenue growth" in FY27, or does growth remain hostage to the timing of individual customer programmes?

Ankur Sharma | 10 September 2026

CRISM Therapeutics Corporation (LSE:CRTX) in Focus: Is This a Biotech Story the Market Is Underestimating?

The question for investors is whether aBusinesswith no revenue, a 2025 loss of £1.9m and aMarket Valueof roughly £8.9m is being priced as a differentiated drug-delivery platform or simply as another cash-hungry small-cap. The coming months, culminating in treatment of the first patient, will …

Ankur Sharma | 10 September 2026

RUA Life Sciences Plc (LSE:RUA) in Focus: Is This a Medical Device Turnaround the Market Is Underestimating?

The question for AIM investors is whether the group can convert that stability into sustained profit while extracting value from the structural heartBusinessit spun out in May 2026 and a French urogynaecology unit bought for a nominal sum. At roughly £16m of market value, …

Ankur Sharma | 10 September 2026

Why Physiomics Plc (LSE:PYC) Deserves a Fresh Look After Its Boardroom Shake-Up

With the new board's first full-year results due within weeks, the question for investors in this £2.3m market-cap company is whether sharper commercial focus can turn a growing order book into a business that stops burning cash.

Ankur Sharma | 10 September 2026

Is Sareum Holdings plc (LSE:SAR) a Sleeper Stock Investors Should Be Watching in 2026?

The question for 2026 is whether aBusinesswith no revenue, £2.5m of cash at its last balance-sheet date and aMarket Valueof around £31m can convert a clean Phase 1 dataset into a licensing deal before its cash runs short. That tension is what makes SAR …

Ankur Sharma | 10 September 2026

Inspiration Healthcare Group PLC (IHC): Could This London Stock Be One of 2026's Most Overlooked Stories?

The question now is whether that momentum has carried into the current year. At its AGM on 23 July, the board said it was "encouraged" by early trading and promised a half-year update in early September. For a small-cap that rarely makes headlines, that …

Divya Sood | 10 September 2026

Why Smith & Nephew plc (SN.) Deserves a Fresh Look as the UK Market Heats Up

The reason is not hard to find. On 4 August 2026 the group cut full-yearRevenuegrowth guidance to around 4% from around 6%, and a fortnight later said chief financial officer John Rogers would leave at the end of September. The question is whether the …

Divya Sood | 10 September 2026

Is BSF Enterprise PLC (BSFA) a Sleeper Stock Investors Should Be Watching in 2026?

The question for anyone eyeing BSFA as a potential sleeper is whether these deals can turn aBusinesswith £18,785 of half-yearRevenueand £60,174 of cash at 31 March 2026 into a self-funding enterprise before dilution does more damage. The FY25 accounts carried a material uncertainty over …

Divya Sood | 10 September 2026
Support

Hi! How can we help you today?

Loading…